Skip to content

Gastroparesis Registry 2

GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01696747
Acronym
GpR2
Enrollment
506
Registered
2012-10-01
Start date
2012-07-31
Completion date
2019-04-30
Last updated
2022-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Gastroparesis, Gastroparesis, Idiopathic Gastroparesis

Keywords

gastroparesis, idiopathic gastroparesis, diabetic gastroparesis, post-Nissen gastroparesis

Brief summary

To expand a registry of patients for the study of the epidemiology, etiology, and degree of morbidity associated with gastroparesis.

Detailed description

The Gastroparesis Registry 2 (GpR 2) will enroll new patients and patients from the initial NIDDK Gastroparesis Clinical Research Consortium Gastroparesis Registry (GpR) of gastroparesis patients which was initiated in February 2007 and completed in March 2011. To continue to follow and expand the data collections of a well-characterized cohort to further define the natural history and clinical course of gastroparesis. To provide a reliable source for recruitment of well-characterized patients with gastroparesis for therapeutic clinical trials, pathophysiological, molecular, histopathologic, or other ancillary studies. These subsequent clinical trials or ancillary studies will be conducted under separate study protocols with separate consent processes.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptoms of gastroparesis of at least 12 weeks duration (do not have to be contiguous) with varying degrees of nausea, vomiting, early satiety, post-prandial fullness, and/or abdominal pain * An etiology of either diabetic, idiopathic, or post-Nissen fundoplication gastroparesis * Gastric emptying scintigraphy of solids and liquids test using 4 hours Egg Beaters® protocol within the last 6 months with either: * Abnormal gastric emptying rate defined as an abnormal 2 hour (\>60% retention) and/or 4 hour (\>10% retention) result based on a 4-hour scintigraphic low fat Egg Beaters® gastric emptying study performed at a GpCRC clinical center. * Patients with a normal gastric emptying rate but with symptoms of gastroparesis may be enrolled and classified as possible gastroparesis or gastroparesis-like with normal gastric emptying * Age at least 18 years at initial screening visit * Upper endoscopy results within last 2 years

Exclusion criteria

* Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs) * Presence of other conditions that could explain the patient's symptoms: * Pyloric or intestinal obstruction as determined by endoscopy, upper GI series or abdominal CT scan * Active inflammatory bowel disease * Known eosinophilic gastroenteritis * Primary neurological conditions that could cause nausea and/or vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions * Acute liver failure * Advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7 ) * Acute renal failure * Chronic renal failure (serum creatinine \>3 mg/dL) and/or on hemodialysis or peritoneal dialysis * Total or subtotal (near complete) gastric resection, esophagogastrostomy, gastrojejunostomy, or gastric bypass. Note: patients with prior fundoplication will be eligible for enrollment. * Any other plausible structural or metabolic cause * Any other condition, which in the opinion of the investigator would interfere with study requirements * Inability to obtain informed consent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026